[go: up one dir, main page]

AU2003242507A1 - A tissue factor binding immunoconjugate comprising factor viia - Google Patents

A tissue factor binding immunoconjugate comprising factor viia

Info

Publication number
AU2003242507A1
AU2003242507A1 AU2003242507A AU2003242507A AU2003242507A1 AU 2003242507 A1 AU2003242507 A1 AU 2003242507A1 AU 2003242507 A AU2003242507 A AU 2003242507A AU 2003242507 A AU2003242507 A AU 2003242507A AU 2003242507 A1 AU2003242507 A1 AU 2003242507A1
Authority
AU
Australia
Prior art keywords
factor
viia
tissue
immunoconjugate
binding immunoconjugate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003242507A
Other languages
English (en)
Other versions
AU2003242507A8 (en
Inventor
Soren E. Bjorn
Else Marie Nicolaisen
Thomas D. Steenstrup
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of AU2003242507A8 publication Critical patent/AU2003242507A8/xx
Publication of AU2003242507A1 publication Critical patent/AU2003242507A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6815—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0815—Tripeptides with the first amino acid being basic
    • C07K5/0817—Tripeptides with the first amino acid being basic the first amino acid being Arg
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0819—Tripeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU2003242507A 2002-07-12 2003-07-09 A tissue factor binding immunoconjugate comprising factor viia Abandoned AU2003242507A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200201099 2002-07-12
DKPA200201099 2002-07-12
PCT/DK2003/000481 WO2004006962A2 (fr) 2002-07-12 2003-07-09 Compose de liaison au facteur tissulaire

Publications (2)

Publication Number Publication Date
AU2003242507A8 AU2003242507A8 (en) 2004-02-02
AU2003242507A1 true AU2003242507A1 (en) 2004-02-02

Family

ID=30011019

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003242507A Abandoned AU2003242507A1 (en) 2002-07-12 2003-07-09 A tissue factor binding immunoconjugate comprising factor viia

Country Status (3)

Country Link
EP (1) EP1523504A2 (fr)
AU (1) AU2003242507A1 (fr)
WO (1) WO2004006962A2 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7348004B2 (en) * 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
DE602004031390D1 (de) * 2003-05-06 2011-03-24 Syntonix Pharmaceuticals Inc Gerinnungsfaktor VII-Fc chimäre Proteine zur Behandlung von hämostatischen Krankheiten
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US20110040073A1 (en) * 2006-04-07 2011-02-17 Novo Nordisk Healthcare A/G Covalent Factor VII-Tissue Factor Complex
RU2375449C2 (ru) * 2007-03-29 2009-12-10 Нейрок Фарма ЛЛС КОДИРУЮЩАЯ ДНК (кДНК) ДЛЯ ПОЛУЧЕНИЯ ВИРУСОПОДОБНЫХ ЧАСТИЦ ВИРУСА ГЕПАТИТА С, СПОСОБ ПОЛУЧЕНИЯ ВИРУСОПОДОБНЫХ ЧАСТИЦ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ИХ ОСНОВЕ
CN102427823A (zh) * 2009-03-24 2012-04-25 拜耳医药保健有限公司 因子viii变体及使用方法
SG10201407983VA (en) * 2009-12-18 2015-01-29 Csl Ltd Method of purifying polypeptides
CA2851223A1 (fr) 2011-10-06 2013-04-11 Hanmi Science Co., Ltd. Derives du facteur vii et viia de coagulation sanguine, conjugues et complexes comprenant ceux-ci, et leur utilisation
CN103599527A (zh) * 2013-08-16 2014-02-26 安源生物科技(上海)有限公司 包含改良型人凝血因子FVII-Fc融合蛋白的药物组合物
CN104774269B (zh) * 2013-08-16 2016-02-24 安源生物科技(上海)有限公司 改良型人凝血因子FVII-Fc融合蛋白及其制备方法与用途
EP3324960A4 (fr) * 2015-07-22 2019-01-23 Iconic Therapeutics, Inc. Procédés permettant de traiter des troubles associés à l'angiogenèse et à une néovascularisation
AU2018341227B2 (en) * 2017-09-27 2024-10-03 Ohio State Innovation Foundation Tissue factor-targeting CAR-NK and CAR-T cell therapy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5788965A (en) * 1991-02-28 1998-08-04 Novo Nordisk A/S Modified factor VII
CA2377381C (fr) * 1999-07-01 2013-06-11 Yale University Immunoconjugues cibles neovasculaires
AU7270600A (en) * 1999-09-20 2001-04-24 Novo Nordisk A/S Bivalent inhibitor of fviia/tf/fxa complex

Also Published As

Publication number Publication date
AU2003242507A8 (en) 2004-02-02
WO2004006962A3 (fr) 2004-03-18
EP1523504A2 (fr) 2005-04-20
WO2004006962A2 (fr) 2004-01-22

Similar Documents

Publication Publication Date Title
AU2003283213A1 (en) A catheter
AU2002253490A1 (en) A catheter
AU2003217713A1 (en) Thrombectomy catheter
AU2003276450A1 (en) Pressurised inhalers
AU2003202910A1 (en) Pivotable strap-buckle assembly
AU2003241882A1 (en) Applicator
AU2003283626A1 (en) Catheter
AU2002255692A1 (en) A cream-t0-powder dermatological composition
AU2003272902A1 (en) Remedies
AU2003242507A1 (en) A tissue factor binding immunoconjugate comprising factor viia
AU2003208404A1 (en) A couplig
AU2003274362A1 (en) Fungicides
AU2003261720A1 (en) Stapler
AU2003236161A1 (en) Stapler
AU2003235325A1 (en) Stapler
AU2003272901A1 (en) Remedies
AU2003244140A1 (en) Catheter
AU2003288418A1 (en) Fungicides
AU2003274380A1 (en) Fungicides
AUPR880401A0 (en) A powered applicator
AUPR247301A0 (en) A board-like sportscraft
AUPS209502A0 (en) Surgical stapler
AU2003280948A1 (en) Fungicides
AU2003218592A1 (en) Starch-based binding agent
AU2002359571A1 (en) A softening-through-the-wash composition

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase